PMLiVE7d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare ...
PMLiVE7d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a ...
PMLiVE11d
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...
PMLiVE14d
Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC
Bristol Myers Squibb’s Opdivo (nivolumab) has been approved by the US Food and Drug Administration (FDA) as part of a perioperative treatment regimen for adults with non-small cell lung cancer (NSCLC) ...
PMLiVE11d
AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn
AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...
PMLiVE8d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...
PMLiVE14d
Chiesi Group invests €400m to establish biotech centre of excellence in Italy
Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested €400m to establish the facility, which it said is dedicated to developing and ...
PMLiVE9d
Merck and Mestag enter inflammatory disease partnership worth up to $1.9bn
Merck & Co – known as MSD outside the US and Canada – has entered into a licence and research collaboration agreement worth up to $1.9bn with Mestag Therapeutics to identify new targets for ...
PMLiVE10d
J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and Astellas’ Xtandi (enzalutamide) in patients with metastatic castration-sensitive ...
PMLiVE9d
PMLiVE’s T40 – results announced!
The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in the UK healthcare sector has been published. The fifth edition of the list ...
PMLiVE16d
Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis
Bristol Myers Squibb (BMS) has announced positive results from a phase 3b/4 study of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in moderate-to-severe scalp psoriasis. Data from the ongoing ...